111Boehringer_Ingelheim_Logo_RGB_Dark_Green (002).png
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
29 juil. 2024 02h05 HE | Boehringer Ingelheim
The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction...
Synlogic_Logo_Blue.png
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
28 mars 2023 06h52 HE | Synlogic, Inc.
CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...